Market: NMS |
Currency: USD
Address: 110 Allen Road
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Show more
📈 Lisata Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$9.50
-
Upside/Downside from Analyst Target:
131.14%
-
Broker Call:
4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
10-25%
-
Net Income Growth Range (1Y):
10-25%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2026-05-08
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Lisata Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-05-07 (estimated upcoming) | - |
| 2025-11-06 | -0.49 |
| 2025-08-07 | -0.54 |
| 2025-05-08 | -0.55 |
| 2025-02-27 | -0.55 |
| 2024-11-12 | -0.59 |
| 2024-08-12 | -0.61 |
| 2024-05-09 | -0.65 |
| 2024-02-29 | -0.66 |
| 2023-11-02 | -0.65 |
| 2023-08-14 | -0.5 |
| 2023-05-09 | -0.77 |
| 2023-03-30 | -0.76 |
| 2022-11-10 | -1.47 |
| 2022-08-04 | -1.65 |
| 2022-05-05 | -1.05 |
| 2022-03-22 | -1.65 |
| 2021-11-04 | -1.8 |
| 2021-08-05 | -1.5 |
| 2021-05-06 | -2.85 |
| 2021-02-25 | -4.2 |
| 2020-11-05 | -4.35 |
| 2020-08-13 | 7.5 |
| 2020-05-08 | -5.7 |
| 2020-03-05 | -7.05 |
📰 Related News & Research
🔍 View more Reports
